Abstract
Aripiprazole is an efficacious treatment for both the positive and negative symptoms of schizophrenia and is also commonly used as a mood stabilizer. It is associated with better tolerability compared with other antipsychotics. However, there are reports of patients who experience problem gambling, hypersexuality, obsessive–compulsive symptoms, and other impulsive and/or compulsive behaviors as a result of aripiprazole administration and/or dosage increase. We aimed to do a systematic review of case reports published in this regard. After screening more than 6000 titles and abstracts in ten scientific search engines, we found 35 related records comprising 59 cases. The majority of cases (n = 42, 71.18%) were male, the mean age was 33.83 years (± 13.40), and the average daily dose of aripiprazole was 11.63 mg (± 6.94). The results of our review showed that the most frequently published impulsivity adverse effect of aripiprazole is gambling, followed by hypersexuality, obsessive–compulsive symptoms/disorder, problem eating, trichotillomania, problem shopping, and kleptomania. These symptoms were experienced both by patients who had previous problems in these areas and those who did not. In the majority of cases, the symptoms appeared within 30 days after aripiprazole administration started and ceased within 30 days of its discontinuation and/or dose decrease. Clinicians should be aware of impulsivity adverse effects, monitor them, and educate both patients and the family about them.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ambrogio F, Martella LA, Odetti P, Monacelli F (2019) Behavioral disturbances in dementia and beyond: time for a new conceptual frame? Int J Mole Sci 20(15):3647. https://doi.org/10.3390/2Fijms20153647
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
*Bulbena-Cabré A, Bulbena A (2016) Aripiprazole-induced hypersexuality.Primary Care Companion CNS Disorders 18(6): 26650https://doi.org/10.4088/pcc.16l01983
Burk BG, DiGiacomo T, Polancich S, Pruett BS, Sivaraman S, Birur B (2023) Antipsychotics and obsessive–compulsive disorder/obsessive–compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system. Acta Psychiatr Scand. https://doi.org/10.1111/acps.13567
*Ceylan ME, Evrensel A, Ünsalver BÖ, Cömert G (2021) Pathological gambling due to aripiprazole: two cases. West Indian Med J69(3): 154-156https://doi.org/10.7727/wimj.2015.107
*Chen HY, Ma CH, Liu CC (2019) Two cases of de novo pathological gambling associated with aripiprazole. Clin Neuropharmacol 42(3): 101-102https://doi.org/10.1097/wnf.0000000000000342
*Cheon E, Koo BH, Seo SS, Lee JY (2013) Two cases of hypersexuality probably associated with aripiprazole. Psychiatry Inv 10(2): 200https://doi.org/10.4306/pi.2013.10.2.200
*Çildir DA, Kalyoncu T (2018) Trichotillomania associated with aripiprazole: a case report. J Clin Psychopharmacol 38(1): 98-99https://doi.org/10.1097/jcp.0000000000000821
*Cohen J, Magalon D, Boyer L, Simon N, Lançon C (2011) Aripiprazole-induced pathological gambling: a report of 3 cases. Curr Drug Saf 6(1):51-53https://doi.org/10.2174/157488611794480016
*Corbeil O, Corbeil S, Giroux I, Jacques C, Dorval M, Demers MF, Roy MA (2020) Problem gambling associated with aripiprazole in first-episode psychosis patients: a series of 6 case reports. J Clin Psychopharmacol 40(2):191-194https://doi.org/10.1007/s40263-021-00801-4
Cox JH, Cavanna AE (2021) Aripiprazole for the treatment of Tourette syndrome. Expert Rev Neurotherapeut 21(4):381–391. https://doi.org/10.4088/2Fpcc.v07n0605
*Das S, Chatterjee SS, Bagewadi V (2017) Aripiprazole induced hypersexuality, when we should be cautious? Asian J Psychiatry 29:162-163https://doi.org/10.1016/j.ajp.2017.05.023
De Micco R, Satolli S, Siciliano M, De Mase A, Giordano A, Tedeschi G, Tessitore A (2022) Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study. Neurol Sci 43(1):357–364. https://doi.org/10.1007/s10072-021-05324-w
Derakhshanpour F, Deylamsalehi A, Moghadda SSJ, Shahini N (2022) Efficacy of aripiprazole and risperidone in treatment of children with attention-deficit/hyperactivity disorder: a double-blind clinical trial study. Bull Pharmaceut Sci Assiut 45(1):281–288. https://doi.org/10.21608/bfsa.2022.239464
*Desarkar P, Das A, Nizamie SH (2007) Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol 27(3): 305-306https://doi.org/10.1097/01.jcp.0000270091.32286.0a
*Dhillon R, Bastiampillai T, Cao CZ, Eckert TG, Tibrewal P (2017) Aripiprazole and impulse-control disorders: a recent FDA warning and a case report. Primary Care Companion for CNS Disorders19(1): 26647https://doi.org/10.4088/pcc.16l02003
Dold M, Aigner M, Lanzenberger R, Kasper S (2015) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 18(9):pyv047. https://doi.org/10.1093/ijnp/pyv047
Doval N, Das S, Moun V (2017) Aripiprazole in tardive dyskinesia: is it a safe choice? J Neurosci Rural Practice 8(02):294–295. https://doi.org/10.4103/jnrp.jnrp_359_16
Downing L, Kim DD, Procyshyn RM, Tibbo P (2019) Management of sexual adverse effects induced by atypical antipsychotic medication. J Psychiatry Neurosci 44(4):287–288. https://doi.org/10.1503/2Fjpn.190053
Endomba FT, Tankeu AT, Nkeck JR, Tochie JN (2020) Leptin and psychiatric illnesses: Does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis 19:1–12. https://doi.org/10.1186/s12944-020-01203-z
Faheem M, Akram W, Akram H, Khan MA, Siddiqui FA, Majeed I (2022) Gender-Based Differences in Prevalence and Effects of ADHD in Adults; a Systematic Review. Asian J Psychiatry 103205. https://doi.org/10.1016/j.ajp.2022.103205
Ferrari E, Fraschini F, Brambilla F (1990) Hormonal circadian rhythms in eating disorders. Biol Psychiat 27(9):1007–1020. https://doi.org/10.1016/0006-3223(90)90037-3
Furukawa Y, Hamza T, Cipriani A, Furukawa TA, Salanti G, Ostinelli EG (2022) Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: Preliminary findings based on a systematic review and dose–effect meta-analysis. Br J Psychiatry 221(2):440–447. https://doi.org/10.1192/bjp.2021.165
Fusaroli M, Giunchi V, Battini V, Gringeri M, Rimondini R, Menchetti M, Poluzzi E (2023) Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study. Psychiatry Clin Neurosci 77(3):160–167. https://doi.org/10.1111/pcn.13511
*Gaboriau L, Victorri-Vigneau C, Gérardin M, Allain-Veyrac G, Jolliet-Evin P, Grall-Bronnec M (2014) Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addictive Behaviors 39(3) 562-565https://doi.org/10.1016/j.addbeh.2013.11.005
*Gavaudan G, Magalon D, Cohen J, Lançon C, Léonetti G, Pélissier‐Alicot AL (2010) Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. J Forensic Sci 55(6):659-1662https://doi.org/10.1111/j.1556-4029.2010.01483.x
Giri YR, Peteru SR (2019) Escalation of gambling associated with aripiprazole: a case report and literature review. J Psychiatric Practice® 25(2):139–145. https://doi.org/10.1097/pra.0000000000000367
Goh CMJ, Asharani PV, Abdin E, Shahwan S, Zhang Y, Sambasivam R,... Subramaniam M (2022) Gender differences in alcohol use: a nationwide study in a multiethnic population. Int J Mental Health Addict 1–15. https://doi.org/10.1007/s11469-022-00921-y
*Golouh V, Celofiga A (2021) Pathological Gambling and Compulsive Eating Associated with Long-Acting Injectable Aripiprazole: A Case Report. Psychiatria Danubina 33(3):373–375. https://doi.org/10.24869/psyd.2021.373
Guo K, Feng Z, Chen S, Yan Z, Jiao Z, Feng D (2022) Safety profile of antipsychotic drugs: analysis based on a provincial spontaneous reporting systems Database. Front Pharmacol 13:848472. https://doi.org/10.3389/fphar.2022.848472
*Gupta P, Gupta R, Balhara YPS (2017) Obsessive-compulsive symptoms associated with aripiprazole treatment in bipolar disorder: a case report. J Clin Psychopharmacol 37(1):108 109https://doi.org/10.1097/jcp.0000000000000629
Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, Noguchi N, Hishimoto A (2023) Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC Psychiatry 23(1):1–7. https://doi.org/10.1186/s12888-023-04617-y
Hing N, Russell A, Tolchard B, Nower L (2016) Risk factors for gambling problems: An analysis by gender. J Gambl Stud 32:511–534. https://doi.org/10.1007/s10899-015-9548-8
IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp
Ichikawa J, Li Z, Dai J, Meltzer HY (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956(2):349–357. https://doi.org/10.1016/S0006-8993(02)03570-9
Johnson J, El-Alfy AT (2016) Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania. J Adv Res 7(2):169–184. https://doi.org/10.1016/j.jare.2015.05.001
*Jones R, Shad M (20190 Aripiprazole-induced kleptomania: Case report. J Affect Disord 244: 242 243https://doi.org/10.1016/j.jad.2018.05.042
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63(9):763–771. https://doi.org/10.4088/jcp.v63n0903
Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD (2021) Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacology Reports 41(2):134–143. https://doi.org/10.1002/2Fnpr2.12180
Kim SW, Shin IS, Kim JM, Youn T, Yang SJ, Hwang MY, Yoon JS (2009) The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clin Neuropharmacol 32(4): 224 226https://doi.org/10.1097/wnf.0b013e318184fafd
Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G (2021) Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach. Clinical Pharmacokinetics 60(12):1569–1582. https://doi.org/10.1007/2Fs40262-021-01041-x
*Kobayashi N, Takano M (2018) Aripiprazole-induced sleep-related eating disorder: a case report. J Med Case Reports 12(1):1-4https://doi.org/10.1186/s13256-018-1622-2
Kodama M, Hamamura T (2010) Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting. Int J Neuropsychopharmacol 13(4):549 551https://doi.org/10.1017/S1461145709990976
Kopelman JM (2020) The role of Slc1a1 in OCD-relevant behavior and associated neural activity (Doctoral dissertation, University of Pittsburgh). 30163899
Kozian R (2019) Hypersexuality induced by aripiprazole. Psychiatr Prax 47(1):43–45. https://doi.org/10.1055/a-0941-3874
Lachance A, Corbeil O, Corbeil S, Chalifour G, Breault AS, Roy MA, Demers MF (2019) Case reports of aripiprazole and problematic gambling in schizophrenia: a critical review of the evidence. J Clin Psychopharmacol 39(4):393–397. https://doi.org/10.1097/JCP.0000000000001068
Lamy M, Erickson CA (2018) Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders. Curr Probl Pediatr Adolesc Health Care 48(10):250–264. https://doi.org/10.1016/j.cppeds.2018.08.015
Li P, Snyder GL, Vanover EK (2016) Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Topics Med Chem 16(29):3385–3403. https://doi.org/10.2174/2F1568026616666160608084834
*Lin C, Chang HM, Huang MC (2020) Aripiprazole-induced obsessive-compulsive symptoms. Taiwanese J Psychiatry 34 1 47https://doi.org/10.4103/TPSY.TPSY_34_19
Martinotti G, Orsolini L, Fornaro M, Vecchiotti R, De Berardis D, Iasevoli F, Di Giannantonio M (2016) Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opinion Inv Drugs 25(6):719–728. https://doi.org/10.1080/13543784.2016.1175431
Mathes BM, Morabito DM, Schmidt NB (2019) Epidemiological and clinical gender differences in OCD. Curr Psychiatry Rep 21:1–7. https://doi.org/10.1007/s11920-019-1015-2
McIntyre RS, Such P, Yildirim M, Madera JM, Zhang Z, Larsen F, Harlin M (2023) Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study. Curr Med Res Opinion, (just-accepted) 39:1–16. https://doi.org/10.1080/03007995.2023.2219155
Merino D, Gérard AO, Van Obberghen EK, Ben Othman N, Ettore E, Giordana B, Drici MD (2022) Medications as a trigger of sleep-related eating disorder: a disproportionality analysis. J Clin Med 11(13):3890. https://doi.org/10.3390/jcm11133890
*Mohan T, Dolan S, Mohan R, Dawson J (2017) Aripiprazole and impulse-control disorders in high-risk patients. Asian J Psychiatr 27:67 68https://doi.org/10.1016/j.ajp.2017.02.015
Montero I, Talavera M, Ruiz I (2008) Clinical trials with a new atypical antipsychotic (Aripiprazole): Gender specific information analysis. Women Health 47(4):39–51. https://doi.org/10.1080/03630240802100051
Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Mu PF (2017) Chapter 7: Systematic reviews of etiology and risk. Joanna Briggs institute reviewer’s manual. The Joanna Briggs Institute 5:217–269. https://doi.org/10.1097/xeb.0000000000000064
Moore TJ, Glenmullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174(12):1930–1933. https://doi.org/10.1001/jamainternmed.2014.5262
*Mouaffak F, Gallarda T, Baylé FJ, Olié JP, Baup N (2007) Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. J Clin Psychopharmacol 27(2): 237 238https://doi.org/10.1097/01.jcp.0000264981.94614.54
*Mousailidis G, Mehboob R, Papanna B, Bhan-Kotwal S, Shoka A (2020) Hypersexuality and new sexual orientation following aripiprazole use. Prog Neurol Psychiatry 24(1):14 16https://doi.org/10.1002/pnp.556
*Nafisa D, Kakunje A (2022) Aripiprazole-induced obsessive–compulsive symptoms. Ind Psychiatry J 31(1):158https://doi.org/10.4103/ipj.ipj_182_20
*Naguy A, Naguy C (2022) Trichotieromania and Alopecia Areata Triggered by Aripiprazole-Methylphenidate Combo in an Autistic Child: The Nexus of Impulsivity-Compulsivity. Psychopharmacol Bull 52(2):157. https://pubmed.ncbi.nlm.nih.gov/35721814
*Oberbarnscheidt T, Miller NS, Henry JG (2017) Abilify-Induced Gambling Disorder: A Case Review. Psychiatry 199(2):158–159. https://doi.org/10.19080/JPCR.2017.04.555641
Padala PR, Wengel SP, Petty F (2007) Manic episode during treatment with aripiprazole. Am J Psychiatry 164(1):172–173. https://doi.org/10.1176/ajp.2007.164.1.172a
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906. https://doi.org/10.1136/bmj.n71
*Peterson E, Forlano R (2017) Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. Australas Psychiatry 25 6 614 616https://doi.org/10.1177/1039856217715996
Pfaus JG (2009) Pathways of sexual desire. J Sex Med 6(6):1506–1533. https://doi.org/10.1111/j.1743-6109.2009.01309.x
Pollmächer T (2015) Treatment of schizophrenia. In: Wright JA, editor. International Encyclopedia of the Social and Behavioral Sciences. 2nd ed. Elsevier 16–20. http://www.elsevier.com/locate/permissionusematerial
*Priya L, Moorthy B (2021) A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia. Case Rep Psychiatry 2021. https://doi.org/10.1155/2F2021/2F5557211
Ramasubbu R, Ravindran A, Lapierre Y (2000) Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 33(06):236–238. https://doi.org/10.1055/s-2000-8360
*Reddy B, Ali M, Guruprasad S, Das S (2017) Hypersexuality induced by Aripiprazole: Two case reports and review of the literature. Asian J Psychiatr 38: 57 59https://doi.org/10.1016/j.ajp.2017.10.008
*Roxanas MG (2010) Pathological gambling and compulsive eating associated with aripiprazole. Aust N Z J Psychiatry 44(3):291 291 https://doi.org/10.3109/00048670903487282
*Scavone C, Stelitano B, Rafaniello C, Rossi F, Sportiello L, Capuano A (2020) Drugs-induced pathological gambling: an analysis of Italian spontaneous reporting system. J Gambling Stud 36:85-96.https://doi.org/10.1007/s10899-019-09828-1
*Schlachetzki JC, Langosch JM (2008) Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? J Clin Psychopharmacol 28(5):567-568https://doi.org/10.1097/jcp.0b013e31818582de
*Smith N, Kitchenham N, Bowden-Jones H (2011) Pathological gambling and the treatment of psychosis with aripiprazole. Br J Psychiatry 199(2):158-159https://doi.org/10.1192/bjp.bp.110.084996
Stajic M (2019) Aripiprazole as a mood stabilizer in postpartum depression with premorbid passive-dependent personality structure. Scr Med 50(4):188–190. https://doi.org/10.5937/scriptamed50-22410
Stefanou MI, Vittore D, Wolz I, Klingberg S, Wildgruber D (2020) Recurrent episodes of paraphilic behavior possibly associated with olanzapine and aripiprazole treatment in a patient with schizophrenia. Front Psych 11:318. https://doi.org/10.3389/fpsyt.2020.00318
Stelmach A, Guzek K, Rożnowska A, Najbar I, Sadakierska-Chudy A (2023) Antipsychotic drug—Aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. Pharmacol Rep 75(1):19–31. https://doi.org/10.1007/s43440-022-00440-6
Thamby A, Jaisoorya TS (2019) Antipsychotic augmentation in the treatment of obsessive-compulsive disorder. Indian J Psychiatry 61(Suppl 1):S51. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_519_18
Tien Y, Huang HP, Liao DL, Huang SC (2022) Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan. Therapeut Adv Psychopharmacol 12:20451253221113240. https://doi.org/10.1177/20451253221113238
Üçok A, İncesu C, Aker T, Erkoç Ş (2007) Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 22(5):328–333. https://doi.org/10.1016/j.eurpsy.2007.01.001
*Usmani MA (2020) Aripiprazole induced compulsive eating in adolescent: Is this the effect of aripiprazole on Serotonin receptors? J Clin Rev Case Rep 5(7):306–308. https://doi.org/10.33140/JCRC
Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Iwamoto T (2005) Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 187(3):235–242. https://doi.org/10.1192/bjp.187.3.235
Wolfschlag M, Håkansson A (2023) Drug-Induced Gambling Disorder: Epidemiology, Neurobiology, and Management. Pharmaceut Med 37(1):37–52. https://doi.org/10.1007/s40290-022-00453-9
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Appendix A
Appendix A
The Full Set of Search Terms related to impulse-control problems and compulsive behaviors
“compulsive, compulsion, compulsivity, compulsive behavior, pathological compulsive behavior, compulsive shopping, compulsive buying, excessive buying, oniomania, compulsive sex, compulsive sexuality, compulsive sexual behavior, compulsive hypersexuality, hypersexuality, sexual behavior, pornography, compulsive interest in sex, compulsive cybersex behavior, compulsive masturbation, compulsive social media use, compulsive alcohol use, compulsive substance use, compulsive gaming, compulsive video gaming, gaming disorder, gaming addiction, compulsive internet use, compulsive gambling, problem gambling, compulsive eating, binge eating, compulsive binge eating, eating disorder, bulimia nervosa, compulsive exercise, compulsive smoking, kleptomania, pyromania, trichotillomania, trich, hair pulling, excoriation, skin-picking, dermatillomania, hoarding, obsessive-compulsive disorder, obsessive-compulsive symptom, OCS, OCD, OCD symptoms, compulsive checking, compulsive washing, compulsive counting, body focused repetitive behavior, nail-biting, impulsive behavior, impulsive control disorder, ICD, compulsive, medication use, hobbyism, punding, suicidality, compulsive self-harm, onychophagia, impulse control disorder, impulsion, compulsive consumption, non-paraphilic compulsive sexual behavior, sexual compulsivity, nymphomania, satyriasis, Obsessive Compulsive Spectrum, compulsive lying, compulsive talking, tic, and Tourette”
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Akbari, M., Jamshidi, S., Sheikhi, S. et al. Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports. Psychopharmacology 241, 209–223 (2024). https://doi.org/10.1007/s00213-024-06529-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-024-06529-5